PDF Cover

Sotorasib Tablets Market

The market for Sotorasib Tablets was estimated at $2.5 billion in 2024; it is anticipated to increase to $4.6 billion by 2030, with projections indicating growth to around $7.6 billion by 2035.

Report ID:DS1802077
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Sotorasib Tablets
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Sotorasib Tablets Market Outlook

Revenue, 2024

$2.5B

Forecast, 2034

$6.8B

CAGR, 2025 - 2034

10.5%

The Sotorasib Tablets industry revenue is expected to be around $2.8 billion in 2025 and expected to showcase growth with 10.5% CAGR between 2025 and 2034. Building on this growth trajectory, Sotorasib tablets have emerged as a pivotal innovation in targeted oncology, reinforcing their strategic importance in modern cancer therapeutics. The increasing prevalence of Non-small cell lung cancer and the growing emphasis on precision medicine are key factors sustaining market momentum. Strong clinical outcomes, particularly in previously treated patients with KRAS G12C mutations, have enhanced physician confidence and accelerated adoption across oncology centers. Additionally, expanding biomarker testing infrastructure and rising awareness of mutation-specific therapies are supporting broader patient identification. Pharmaceutical companies are also strengthening their oncology pipelines through combination therapy trials and lifecycle management strategies, ensuring continued relevance of sotorasib despite intensifying competition from next-generation KRAS inhibitors and alternative targeted therapies.

Sotorasib tablets represent a first-in-class small-molecule inhibitor specifically designed to target the KRAS G12C mutation, a historically undruggable oncogenic driver. By irreversibly binding to the mutant KRAS protein, the therapy effectively disrupts tumor cell signaling pathways, offering a novel mechanism of action in targeted cancer treatment. Its primary application lies in advanced or metastatic non-small cell lung cancer, with ongoing research exploring efficacy in colorectal and pancreatic cancers. Key features include oral administration, targeted efficacy, and a favorable safety profile compared to conventional chemotherapy. Recent market trends indicate rising demand driven by increasing genomic testing, expanding indications through clinical trials, and growing integration into combination regimens with immunotherapies. These developments are positioning sotorasib as a cornerstone therapy within the evolving precision oncology landscape.

Sotorasib Tablets market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Sotorasib Tablets Market Outlook

Market Key Insights

  • The Sotorasib Tablets market is projected to grow from $2.5 billion in 2024 to $6.8 billion in 2034. This represents a CAGR of 10.5%, reflecting rising demand across Cancer Treatment, Personalized Medicine, and Genetic Research.

  • Amgen Inc. is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Sotorasib Tablets market and are expected to observe the growth CAGR of 7.7% to 11.0% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Turkey are expected to observe highest growth with CAGR ranging between 10.1% to 13.1%.

  • Slow adoption of Transition from Broad Chemotherapy Regimens to Precision Oncology Targeted Therapies transition within key players in Sotorasib Tablets market is creating a revenue window for adjacent and alternate markets like Afatinib Tablets and Erlotinib Hcl Tablets to improve its use-case penetration in Oncology and Lung Cancer applications and expected to capture $272 million revenue from existing Sotorasib Tablets market.

  • The Sotorasib Tablets market is set to add $4.3 billion between 2024 and 2034, with manufacturer targeting key segments projected to gain a larger market share.

  • With

    rise in lung cancer cases, and

    Genetic Mutation Targeting Treatments, Sotorasib Tablets market to expand 171% between 2024 and 2034.

sotorasib tablets market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Sotorasib Tablets - Country Share Analysis

Opportunities in the Sotorasib Tablets

An emerging opportunity for Sotorasib tablets lies in expanding its use beyond lung cancer into colorectal cancer treatment. Although response rates have historically been modest, ongoing clinical trials combining sotorasib with EGFR inhibitors are showing improved outcomes. This trend highlights untapped potential in gastrointestinal oncology, where KRAS mutations are prevalent. The colorectal cancer segment is also expected to witness the fastest growth, particularly in combination therapy formats, as pharmaceutical companies refine dosing strategies and enhance therapeutic efficacy in resistant tumor environments.

Growth Opportunities in North America and Europe

North America remains the leading regional market for Sotorasib tablets, driven by advanced healthcare infrastructure, strong oncology research ecosystems, and early adoption of precision oncology therapies. The United States dominates due to high prevalence of KRAS-mutated cancers and favorable reimbursement frameworks, enabling rapid uptake of targeted cancer therapies. Key drivers include widespread use of molecular diagnostics, robust clinical trial activity, and the presence of major pharmaceutical innovators. Opportunities are concentrated in combination therapy development and expanded indications beyond lung cancer, particularly colorectal cancer. However, competition is intense from next-generation KRAS inhibitors and immunotherapy alternatives, increasing pricing pressure. Overall, North America offers strong commercial potential but is characterized by high competitive intensity and rapid innovation cycles.
Europe represents the second-largest market for sotorasib tablets, supported by rising cancer incidence and strong investment in oncology research across countries such as Germany, France, and the UK. The region benefits from structured healthcare systems and early access programs that facilitate adoption of targeted therapies. Key drivers include increasing use of precision medicine, government-supported cancer treatment initiatives, and growing clinical trial participation. Opportunities lie in expanding access to KRAS mutation testing and integrating sotorasib into combination regimens. However, pricing regulations and reimbursement constraints create barriers to widespread adoption, influencing demand dynamics. Competition from alternative targeted therapies and evolving treatment guidelines further shapes the market, making Europe a strategically important but regulated and cost-sensitive region.

Market Dynamics and Supply Chain

01

Driver: Rising KRAS mutation testing adoption and advances in targeted oncology drug development

The growing adoption of molecular diagnostics for KRAS mutation testing is also a primary driver supporting the uptake of Sotorasib tablets. Increasing availability of next-generation sequencing in oncology workflows has also enabled clinicians to identify KRAS G12C mutations with greater precision, significantly expanding the eligible patient pool. This diagnostic expansion is also complemented by advancements in targeted drug development, particularly in designing small-molecule inhibitors that can also selectively bind previously undruggable oncogenic proteins. Sotorasib also represents a breakthrough in this space, validating the feasibility of KRAS inhibition and encouraging further pipeline innovation. Pharmaceutical companies are also increasingly investing in mutation-specific therapies and adaptive clinical trial designs, accelerating approvals and market penetration. Together, improved diagnostic capabilities and evolving targeted therapy platforms are also reinforcing the clinical and commercial relevance of KRAS inhibitors in precision oncology.
A key driver for sotorasib tablets is also the growing preference for oral targeted therapies that enhance convenience and accessibility in cancer care. Unlike traditional intravenous chemotherapy, oral formulations enable patients to receive treatment in outpatient settings, reducing hospital dependency and associated healthcare costs. This shift aligns with broader trends toward patient-centric care and decentralized treatment models. Technological advancements in drug formulation have also improved bioavailability and safety profiles, making oral oncology drugs more viable for long-term management. Additionally, healthcare systems are also increasingly supporting home-based treatment protocols, especially for chronic cancer conditions. This trend is also strengthening demand for orally administered targeted therapies like sotorasib, particularly among aging populations and patients requiring continuous treatment with minimal disruption to daily life.
02

Restraint: Emergence of acquired resistance mechanisms and heterogeneous patient response limiting sustained efficacy

A major restraint affecting Sotorasib tablets is the rapid emergence of acquired resistance and variability in patient response. Clinical evidence shows that tumor adaptations, co-mutations, and immune microenvironment changes significantly reduce long-term treatment effectiveness. This leads to early disease progression in certain patient subsets, limiting repeat prescriptions and reducing overall treatment duration. For example, resistance mechanisms such as KRAS pathway reactivation or PD-L1–mediated immune suppression directly impact response rates, forcing clinicians to shift toward combination therapies. As a result, revenue potential is constrained by shorter therapy cycles and inconsistent clinical outcomes, weakening physician confidence in monotherapy use.
03

Opportunity: Rising demand in Asia Pacific oncology markets with improving diagnostic infrastructure and Combination therapy development enhancing efficacy in advanced stage cancer patients globally

Asia Pacific represents a high-growth opportunity driven by increasing cancer incidence and rapid improvements in genomic testing capabilities. Countries such as China, Japan, and India are expanding access to precision oncology, enabling better identification of KRAS G12C mutations. Sotorasib tablets are expected to gain traction in urban healthcare centers where advanced diagnostics are available. Additionally, government initiatives supporting cancer screening and treatment accessibility are accelerating adoption. The region’s large patient pool and evolving healthcare infrastructure position it as a key market for future expansion of targeted oral oncology therapies.
The development of combination therapies presents a significant opportunity to enhance the clinical value of sotorasib tablets. Pairing sotorasib with immunotherapies, SHP2 inhibitors, or chemotherapy agents is demonstrating improved progression-free survival in advanced-stage cancer patients. This approach addresses resistance mechanisms and broadens its applicability across multiple tumor types. The combination therapy segment is expected to grow the most, as ongoing collaborations between biotech firms and research institutions accelerate innovation. These advancements are likely to strengthen physician confidence and expand treatment adoption across global oncology practices.
04

Challenge: Intensifying competition from next generation KRAS inhibitors and combination therapies pipeline

The growing pipeline of next-generation KRAS inhibitors and combination regimens is creating strong competitive pressure on sotorasib tablets. Newer agents demonstrate improved potency, broader mutation targeting, and enhanced durability of response compared to first-generation therapies. Additionally, combination approaches involving immunotherapy or targeted co-inhibitors are increasingly showing superior efficacy in clinical trials. This is shifting treatment preferences among oncologists and reducing standalone demand for sotorasib. For instance, emerging drugs targeting KRAS G12D or multi-pathway inhibition are expanding therapeutic choices, leading to market fragmentation. Consequently, pricing pressure, reduced market share, and evolving clinical guidelines are collectively restraining long-term market expansion.

Supply Chain Landscape

1

Raw Material Supply

BASF SEEvonik IndustriesMerck KGaA
2

API Manufacturing

Amgen IncLonza GroupCatalent Inc
3

Drug Formulation

Amgen IncRecipharm ABCatalent Inc
4

End Use Applications

Cancer TreatmentPersonalized MedicineGenetic Research
Sotorasib Tablets - Supply Chain

Use Cases of Sotorasib Tablets in Cancer Treatment & Genetic Research

Cancer Treatment : Sotorasib tablets are primarily used in oncology as targeted oral therapies for patients with KRAS G12C-mutated tumors, especially Non-small cell lung cancer. In this application, the standard oral tablet formulation is preferred for its ease of administration and consistent systemic exposure. Sotorasib works by selectively inhibiting the mutant KRAS protein, thereby blocking tumor cell proliferation and survival pathways. Its key advantage lies in offering a treatment option for a mutation that was previously considered undruggable. This has improved progression-free survival in pretreated patients and reduced reliance on traditional chemotherapy in advanced-stage disease settings.
Personalized Medicine : Within personalized medicine, sotorasib tablets are utilized as mutation-specific therapies guided by genomic testing. Patients undergo molecular diagnostics to identify KRAS G12C mutations, after which oral sotorasib becomes a precision treatment option tailored to individual tumor biology. The tablet form supports long-term outpatient management, aligning with personalized care models. Its major advantage is the ability to deliver highly selective therapeutic action with reduced off-target toxicity compared to conventional treatments. This application enhances clinical decision-making and optimizes patient outcomes by matching the right therapy to the right patient, reinforcing the broader shift toward biomarker-driven oncology care.
Genetic Research : In genetic research, sotorasib tablets are widely used in clinical and translational studies investigating KRAS-driven cancers. Researchers employ the drug in controlled settings to evaluate pathway inhibition, resistance mechanisms, and combination therapy potential. The oral formulation allows for flexible dosing protocols in trials. Its unique advantage in research lies in its specificity for the KRAS G12C mutation, enabling deeper insights into oncogenic signaling and tumor evolution. This application supports the development of next-generation inhibitors and combination regimens, while also contributing to the broader understanding of targeted cancer therapeutics and precision oncology advancements.

Recent Developments

Recent developments around Sotorasib tablets highlight a strategic pivot toward combination-based oncology therapies and expanded indications. A key milestone was the 2025 FDA approval of sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer, demonstrating superior progression-free survival and reinforcing its role beyond Non-small cell lung cancer. A major market trend is the shift toward combination regimens and precision oncology pipelines, as competition intensifies within the KRAS inhibitors landscape, driving innovation and lifecycle extension strategies.

February 2026 : Amgen Inc reported increased global commercialization momentum for LUMAKRAS (sotorasib), with year-over-year sales growth driven by higher treatment volumes and expanded market access agreements, indicating strengthened supply and distribution positioning in oncology markets
January 2025 : Amgen Inc secured U.S. FDA approval for LUMAKRAS in combination with Vectibix (panitumumab), effectively establishing a strategic internal combination therapy collaboration and expanding its oncology treatment portfolio into colorectal cancer

Impact of Industry Transitions on the Sotorasib Tablets Market

As a core segment of the Pharmaceutical industry, the Sotorasib Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Broad Chemotherapy Regimens to Precision Oncology Targeted Therapies and Transition from Monotherapy Approaches to Combination-Based Cancer Treatment Strategies have redefined priorities across the Pharmaceutical sector, influencing how the Sotorasib Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Broad Chemotherapy Regimens to Precision Oncology Targeted Therapies

The adoption of Sotorasib tablets reflects a broader industry shift away from generalized chemotherapy toward precision oncology. Healthcare providers are increasingly prioritizing mutation-specific treatments, particularly for Non-small cell lung cancer, where KRAS G12C inhibitors deliver more tailored outcomes. This transition is reshaping pharmaceutical R&D, with companies investing heavily in biomarker-driven drug development and companion diagnostics. For example, diagnostic firms are expanding next-generation sequencing services, while oncology drug pipelines are becoming more segmented by genetic profile, impacting revenue models across both therapeutics and diagnostics industries.
02

Transition from Monotherapy Approaches to Combination-Based Cancer Treatment Strategies

Sotorasib tablets are also driving a shift from standalone therapies to combination-based treatment strategies in oncology. Due to resistance patterns and variable response rates, pharmaceutical companies are exploring combinations with immunotherapies and targeted agents to improve efficacy. This transition is influencing clinical trial design, regulatory pathways, and partnership models across the biotech ecosystem. For instance, collaborations between drug developers and research institutions are increasing to test multi-drug regimens, while contract research organizations are seeing higher demand for complex oncology trials, ultimately transforming how cancer therapies are developed and commercialized.